Abstract
Aims
To evaluate the efficacy of a closed-loop (AHCL) system in restoring awareness of
hypoglycemia in patients with type 1 diabetes (T1D).
Methods
We conducted a prospective study including 46 subjects with T1D flash glucose monitoring
(FGM) or continuous glucose monitoring (CGM) switching to a Minimed 780G® system.
Patients were classified in three groups according to the therapy used before switching
to Minimed® 780G: multiple dose insulin (MDI) therapy + FGM (n=6), continuous subcutaneous
insulin infusion + FGM (n=21), and sensor-augmented pump with predictive low-glucose
suspend (n=19). FGM/CGM data were analyzed at baseline, after 2 and 6 months on AHCL.
Clarke’s score of hypoglycemia awareness was compared at baseline and 6 months recordings.
We also compared the efficacy of the AHCL system in improving A1c among patients with appropriate perception of symptoms of hypoglycemia compared to
those presenting with impaired awareness of hypoglycemia (IAH).
Results
Participants had a mean age of 37±15 and a diabetes duration of 20±10 years. At baseline,
12 patients (27%) showed IAH as defined by a Clarke’s score ≥3. Patients with IAH
were older and had lower estimated glomerular filtration rate (eGFR) compared with
those who did not have IAH; with no differences in baseline CGM metrics or A1c. An overall decrease in A1c was observed after 6 months on AHCL (from 6.9±0.5% to 6.7±0.6%, P<0.001), regardless of prior insulin therapy. The improvement in metabolic control
was greater in patients with IAH, showing a reduction in A1c from 6.9±0.5 to 6.4±0.4% vs 6.9±0.5 to 6.8±0.6% (P=0.003), showing a parallel increase in total daily boluses of insulin and automatic
bolus correction administered by the AHCL system. In patients with IAH Clarke’s score
decreased from 3.6±0.8 at baseline to 1.9±1.6 after 6 months (P<0.001). After 6 months on AHCL, only 3 patients (7%) presented with a Clarke’s score
≥3, resulting in an absolute risk reduction of 20% (95% confidence interval: 7–32)
of having IAH.
Conclusions
Switching from any type of insulin administration to AHCL improves restoration of
hypoglycemia awareness and metabolic control in patients with T1D, particularly in
adults with impaired perception of hypoglycemia symptoms.
Trial Registration
ClinicalTrial.gov ID NCT04900636.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Diabetes Research and Clinical PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes.Diabet Med. 2008; 25: 501-504
- Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia.Diabetes Care. 1994; 17: 697-703
- Mechanisms of hypoglycemia-associated autonomic failure in diabetes.N Engl J Med. 2013; 369: 362-372
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.N Engl J Med. 2019; 381: 1707-1717
- Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial.Diabetes Technol Ther. 2021; 23: 342-349
- Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized.Controlled Trial. Diabetes Care. 2020; 43: 3024-3033
- Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.Diabetes Care. 2021; 44: 969-975
- Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.Lancet. 2018; 392: 1321-1329
- Impaired awareness of hypoglycaemia: a review.Diabetes Metab. 2010; 36 Suppl 3(3): S64-S74
- Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice.Endocr Rev. 2022; 6
(2021) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(Suppl 1): S15-S33
- Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.Diabetes Care. 2013; 36: 1384-1395
- Assessing impaired hypoglycemia awareness in type 1 diabetes: agreement of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia.Diabetes Care. 2000; 23: 529-532
- Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms.Diabetes Care. 1995; 18: 517-522
- Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis.Diabetes Care. 2015; 38: 1592-1609
- Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS).Diabetes Care. 2014; 37: 2114-2122
- Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial.Diabetes Care. 2018; 41: 1600-1607
- Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.Lancet Diabetes Endocrinol. 2016; 4: 893-902
- A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia.Diabet Med. 2018; 35: 483-490
- Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.Lancet. 2018; 391: 1367-1377
- Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes.Diabetes Care. 2013; 36: 4160-4162
- Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.Diabetes Technol Ther. 2019; 21: 356-363
- Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial.Lancet Digit Health. 2020; 2: e64-e73
- Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.Diabetes Care. 2021; 44: 1630-1640
- Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.Diabetes Technol Ther. 2018; 20: 189-196
- (2021) Characterizing Glycemic Control and Sleep in Adults with Long-Standing Type 1 Diabetes and Hypoglycemia Unawareness Initiating Hybrid Closed Loop Insulin Delivery.J Diabetes Res. 2021; 6611064: 6611064
- Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.Diabetes Technol Ther. 2022; 24: 178-189
- Impact of Hybrid Closed Loop Therapy on Hypoglycemia Awareness in Individuals with Type 1 Diabetes and Impaired Hypoglycemia Awareness.Diabetes Technol Ther. 2021; 23: 482-490
- Differentiating Hypoglycemia Awareness Status from Hypoglycemia Experience in Tools for Measuring Impaired Awareness of Hypoglycemia.Diabetes Technol Ther. 2020; 22: 541-545
- Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes.Diabetes Technol Ther. 2018; 20: 395-402
- Accuracy of FreeStyle Libre in Adults with Type 1 Diabetes: The Effect of Sensor Age.Diabetes Technol Ther. 2020; 22: 203-207
Article info
Publication history
Accepted:
March 13,
2023
Received in revised form:
February 20,
2023
Received:
January 14,
2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier B.V. All rights reserved.
